Heart failure & cardiomyopathies
Gut Microbiota-Generated Phenylacetylglutamine and Heart Failure
Authors' conclusion
The present study reveals the gut microbial metabolite PAGln is clinically and mechanistically linked to HF presence and severity.
Study context
- Population
- Subjects undergoing coronary angiography in tertiary referral centres
- Participants
- 3,256 vs 829
- Exposure
- Plasma PAGln levels in relation to heart failure (HF) presence and severity
- USn = 3,256
- Europeann = 829
- Outcome
- Association of plasma PAGln with HF, LVEF and NT-proBNP
Methodological details2 independent cohorts (discovery and validation), tertiary referral centres
- 2 independent cohorts (discovery and validation)
- Tertiary referral centres
Main finding
As reported in the abstract
PAGln and HF presence and severity
- Circulating PAGln levels dose-dependently associated with HF presence and severity indices (reduced EF, elevated NT-proBNP), independent of traditional risk factors and renal function, in both cohorts
Observational data: associations, not effects.
Further findings
Mechanistic studies (cultured cardiomyoblasts, murine atrial tissue)
- PAGln and murine counterpart phenylacetylglycine directly fostered HF-relevant phenotypes, incl. decreased cardiomyocyte sarcomere contraction and BNP gene expression
Original publication
Gut Microbiota-Generated Phenylacetylglutamine and Heart Failure. Circ Heart Fail. Published 16 December 2022. doi:10.
Summarised from the published abstract; every number is checked against it